Poolbeg Pharma has identified multiple new drug targets for the treatment of influenza. This marks a “significant” breakthrough in its artificial intelligence programme with medtech company CytoReason. Poolbeg has been

Poolbeg Pharma – a company concentrating on infectious diseases – has announced an update on its oral vaccine programme. It follows the award of non-dilutive grant funding by the Irish

Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with high unmet medical needs, announces an update to its Oral Vaccine Programme following the award of non-dilutive grant

Respiratory syncytial virus is a common illness that causes cold-like symptoms. But for premature babies and those with lung issues, RSV can be fatal. Most children get RSV. The typical

Artificial intelligence appears poised to transform many aspects of our lives, and drug discovery is no exception. By removing much of the trial and error from drug discovery, AI reveals

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost

Respiratory syncytial virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and

The role of artificial intelligence (AI) in therapeutic research has become increasingly prominent in recent years, with the potential to revolutionize drug discovery, testing, and personalized medicine. This transformative technology